HomeCompareHTGM vs ARCC

HTGM vs ARCC: Dividend Comparison 2026

HTGM yields 416.67% · ARCC yields 10.65%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HTGM wins by $15446.83M in total portfolio value
10 years
HTGM
HTGM
● Live price
416.67%
Share price
$0.48
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$15446.85M
Annual income
$10,492,957,272.45
Full HTGM calculator →
ARCC
Ares Capital Corporation
● Live price
10.65%
Share price
$18.02
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.14
Full ARCC calculator →

Portfolio growth — HTGM vs ARCC

📍 HTGM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHTGMARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HTGM + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HTGM pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HTGM
Annual income on $10K today (after 15% tax)
$35,416.67/yr
After 10yr DRIP, annual income (after tax)
$8,919,013,681.58/yr
ARCC
Annual income on $10K today (after 15% tax)
$905.66/yr
After 10yr DRIP, annual income (after tax)
$0.97/yr
At 15% tax rate, HTGM beats the other by $8,919,013,680.61/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HTGM + ARCC for your $10,000?

HTGM: 50%ARCC: 50%
100% ARCC50/50100% HTGM
Portfolio after 10yr
$7723.44M
Annual income
$5,246,478,636.79/yr
Blended yield
67.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

HTGM
Analyst Ratings
8
Buy
Consensus: Buy
Price Target
$0.17
-65.3% upside vs current
Range: $0.17 — $0.17
Altman Z
-35.3
Piotroski
3/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+21.4% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HTGM buys
0
ARCC buys
0
No recent congressional trades found for HTGM or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHTGMARCC
Forward yield416.67%10.65%
Annual dividend / share$2.00$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$15446.85M$24.5K
Annual income after 10y$10,492,957,272.45$1.14
Total dividends collected$14996.03M$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy
Analyst price target$0.17$21.88

Year-by-year: HTGM vs ARCC ($10,000, DRIP)

YearHTGM PortfolioHTGM Income/yrARCC PortfolioARCC Income/yrGap
1← crossover$52,367$41,666.67$11,373$532.74+$41.0KHTGM
2$259,952$203,920.04$12,608$279.46+$247.3KHTGM
3$1,224,201$946,051.97$13,809$142.90+$1.21MHTGM
4$5,473,698$4,163,802.84$15,042$72.20+$5.46MHTGM
5$23,256,265$17,399,408.07$16,341$36.27+$23.24MHTGM
6$93,973,351$69,089,147.58$17,732$18.18+$93.96MHTGM
7$361,461,534$260,910,048.59$19,231$9.10+$361.44MHTGM
8$1,324,680,829$937,916,987.81$20,851$4.55+$1324.66MHTGM
9$4,629,809,751$3,212,401,263.77$22,605$2.28+$4629.79MHTGM
10$15,446,853,706$10,492,957,272.45$24,504$1.14+$15446.83MHTGM

HTGM vs ARCC: Complete Analysis 2026

HTGMStock

HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq DLBCL cell of origin assay; HTG EdgeSeq Oncology Biomarker Panel; HTG EdgeSeq ALKPlus assay EU; HTG EdgeSeq Pan B-Cell Lymphoma Panel; HTG immune response panel; and HTG mouse mRNA tumor response panel. The company distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. has a governing agreement with QIAGEN Manchester Limited. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.

Full HTGM Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this HTGM vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HTGM vs SCHDHTGM vs JEPIHTGM vs OHTGM vs KOHTGM vs MAINHTGM vs HTGCHTGM vs GBDCHTGM vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.